Epic Sciences, founded in 2008, is a diagnostics company seeking to to improve cancer management. The company aims to provide easily accessible and real-time biopsy material to guide personalized medicine for numerous pharmaceutical companies and major cancer centers. The Epic Sciences platform is designed with the goal of identifying and characterizing rare cells including circulating tumor cells ("CTCs"). Epic Sciences is headquartered in San Diego, California.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
12/29/2023 | Series A-3 | $20.9MM | $xx.xx | $94.14MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
6,966,666
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
11/14/2023 | Series A-1b | $20.99MM | $xx.xx | $71.45MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
6,996,739
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
11/14/2023 | Series A-2 | $13.99MM | $xx.xx | $71.45MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,664,492
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
04/19/2023 | Series A-1a | $22.17MM | $xx.xx | $110.87MM | Arsenal Capital Partners, Blue Ox Healthcare Partners, Deerfield Management, Domain Ventures, Labcorp | |
Price per Share
$xx.xx
Shares Outstanding
7,391,119
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arsenal Capital Partners, Blue Ox Healthcare Partners, Deerfield Management, Domain Ventures, Labcorp
|